Alnylam Pharmaceuticals
ALNY
477 hedge funds and large institutions have $24B invested in Alnylam Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 55 funds opening new positions, 172 increasing their positions, 170 reducing their positions, and 54 closing their positions.
22% more call options, than puts
Call options by funds: $194M | Put options by funds: $159M
2% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 54
1% more repeat investments, than reductions
Existing positions increased: 172 | Existing positions reduced: 170
0.63% less ownership
Funds ownership: 96.98% → 96.36% (-0.63%)
2% less funds holding
Funds holding: 487 → 477 (-10)
15% less capital invested
Capital invested by funds: $28.3B → $24B (-$4.38B)
64% less funds holding in top 10
Funds holding in top 10: 14 → 5 (-9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$338M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$107M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$98.4M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$97.7M |
| 5 |
Corient Private Wealth
Miami,
Florida
|
+$56.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$162M |
| 2 |
Dodge & Cox
San Francisco,
California
|
-$146M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$125M |
| 4 |
Holocene Advisors
New York
|
-$122M |
| 5 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$77.5M |
ALNY Hedge Fund Activity: Q1 2023 in Review
477 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q1 2023, worth a combined $24B — down 15% from $28.3B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new ALNY positions and 54 closed out — a net gain of 1 holder — while 172 added to existing stakes and 170 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $338M. The largest seller was Baillie Gifford & Co, cutting an estimated $162M.
- 477 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q1 2023, down from 487 in Q4 2022.
- Funds reported $24B of Alnylam Pharmaceuticals stock for Q1 2023, down 15% quarter-over-quarter.
- 55 funds opened new Alnylam Pharmaceuticals positions in Q1 2023 and 54 closed out, a net change of +1 holder.
- The largest Alnylam Pharmaceuticals buyer in Q1 2023 was Capital Research Global Investors, an estimated $338M added.
- The largest Alnylam Pharmaceuticals seller in Q1 2023 was Baillie Gifford & Co, an estimated $162M sold.
Based on aggregated 13F filings for Q1 2023.